March 3, 2021
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer, The Chase Group utilized its knowledge of the life sciences industry and vast network to successfully fill this key leadership position. Dr. Juergen Froehlich brings a broad range of therapeutic planning and hands-on execution across all phases of clinical development with an extensive track record of successful development projects and oversight. The Chase Group appreciated the partnership with Arcturus to find the executive leader who would help them make a positive impact through the advancement of mRNA medicines and the design and utilization of lipid-mediated drug delivery systems. For more information on how The Chase Group can assist in building your executive team, visit www.chasegroup.com.
